改善因感染住院的癌症患者的经验性抗生素选择:INSPIRE整群随机试验的二次分析
该研究为4项INSPIRE整群随机临床试验的二次分析,纳入36861例因肺炎、尿路感染、皮肤软组织感染或腹腔感染住院的非危重癌症成人患者。计算机化医嘱录入提示在耐药感染风险低于10%时推荐标准谱抗生素,使各试验的广谱抗生素治疗天数降低17%至27%,且两组安全性结局变化相似。
要点
- 计算机化医嘱录入提示在耐药感染风险低于10%时推荐标准谱抗生素。
- 肺炎试验广谱抗生素治疗天数降低27%(RR 0.73,95%CI 0.67-0.80)。
- 尿路感染、皮肤软组织感染和腹腔感染试验分别降低24%、17%和24%。
核心结论
- 包含计算机化医嘱录入提示的抗生素管理集束化策略与癌症患者广谱抗生素使用减少相关,且未观察到安全性结局差异。
研究设计与样本
- 4项INSPIRE整群随机临床试验的二次分析,纳入非危重住院成人(年龄≥18岁)且出院诊断编码为血液系统或实体器官恶性肿瘤的患者。
- 共纳入36861例癌症患者,平均(标准差)年龄69.0(13.6)岁,女性19076例(52%),包括基线组18272例和干预组18589例。
- 采用按随机分组、调整的差分中的差分分析,广义线性混合效应模型,并按患者、医院和时段进行聚类。
主要发现
- 肺炎试验广谱抗生素治疗天数降低27%(率比[RR] 0.73;95%CI 0.67-0.80;P < .001)。
- 尿路感染试验广谱抗生素治疗天数降低24%(RR 0.76;95%CI 0.68-0.84;P < .001)。
- 皮肤软组织感染试验广谱抗生素治疗天数降低17%(RR 0.83;95%CI 0.74-0.92;P < .001)。
- 腹腔感染试验广谱抗生素治疗天数降低24%(RR 0.76;95%CI 0.69-0.84;P < .001)。
- 两组在医院住院时长、重症监护室转入、再入院和院内死亡率方面的前后变化相似。
关键数值与推荐
- 计算机化医嘱录入提示利用实时患者特异性电子健康记录数据估算广谱抗生素处方患者的多重耐药菌感染风险。
- 当抗生素耐药感染风险低于10%时,提示推荐使用标准谱抗生素。
临床怎么用
- 作者认为,研究结果支持采用可扩展、低负担的策略改善癌症患者的抗菌药物使用,该人群指导抗生素管理的证据有限。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「局限性」,故未列出该栏;全文请点「阅读原文」。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
JAMA Netw Open. 2026 Jun 1;9(6):e2616611. doi: 10.1001/jamanetworkopen.2026.16611. ABSTRACT IMPORTANCE: Patients with cancer are routinely prescribed extended-spectrum antibiotics despite overall low multidrug-resistant organism (MDRO) prevalence. Evidence for effective strategies to reduce antibiotic overuse in this population is limited. OBJECTIVE: To evaluate the association of computerized provider order entry (CPOE) prompts providing patient- and pathogen-specific MDRO risk estimates with empiric extended-spectrum antibiotic use in patients with cancer. DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of the 4 Intelligent Stewardship Prompts to Improve Real-Time Empiric Antibiotic Selection (INSPIRE) cluster randomized clinical trials identified non-critically ill hospitalized adults (aged ≥18 years) with discharge diagnosis codes for hematologic or solid organ malignant tumors in the INSPIRE pneumonia, urinary tract infection (UTI), abdominal, and skin and soft tissue infection (SSTI) trials. INTERVENTION: Each trial evaluated the effect of CPOE prompts that used real-time patient-specific electronic health record data to estimate MDRO infection risk for patients prescribed extended-spectrum antibiotics during the first 3 hospital days; the prompt recommended standard-spectrum antibiotics when the risk of antibiotic-resistant infection was less than 10%. MAIN OUTCOMES AND MEASURES: Extended-spectrum antibiotic days of therapy were evaluated using as-randomized, adjusted difference-in-difference analyses with generalized linear mixed-effects models and clustering by patient, hospital, and period. Days to intensive care unit transfer, hospital length of stay, hospital readmissions, and in-hospital mortality were also assessed. RESULTS: In all trials, 36 861 patients (mean [SD] age, 69.0 [13.6] years; 19 076 [52%] female), including 18 272 baseline and 18 589 intervention patients, had cancer. Extended-spectrum antibiotic days of therapy decreased by 27% (rate ratio [RR], 0.73; 95% CI, 0.67-0.80; P < .001) in the pneumonia trial, 24% (RR, 0.76; 95% CI, 0.68-0.84; P < .001) in the UTI trial, 17% (RR, 0.83; 95% CI, 0.74-0.92; P < .001) in the SSTI trial, and 24% (RR, 0.76; 95% CI, 0.69-0.84; P < .001) in the abdominal infection trial. Pre-post changes in hospital length of stay, intensive care unit transfers, readmissions, and in-hospital mortality were similar in the 2 groups. CONCLUSIONS AND RELEVANCE: In this secondary analysis of randomized clinical trials, an antibiotic stewardship bundle that included CPOE prompts recommending standard-spectrum antibiotics for patients at low risk for antimicrobial-resistant infections was associated with reduced extended-spectrum antibiotic use in non-critically ill patients with cancer who were hospitalized with community-acquired pneumonia, UTI, SSTI, or abdominal infection, without observed differences in safety outcomes. The findings support scalable, low-burden strategies to improve antimicrobial use in patients with cancer, a population with limited evidence to guide stewardship. Trial registration ClinicalTrials.gov Identifiers: NCT05423756, NCT05423743, NCT03697070, NCT03697096.
引用
- PubMed 高证据 · 肺炎:Improving Empiric Antibiotic Selection for Patients With Cancer Hospitalized With Infection: Secondary Analysis of the INSPIRE Cluster Randomized Trials
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。